Rejoni, Inc. Company Profile

Background

Founded in June 2020 and headquartered in Bedford, Massachusetts, Rejoni, Inc. is a privately held medical technology company dedicated to advancing women's health through the development and commercialization of innovative gynecological products. Leveraging proprietary biomaterials, Rejoni aims to enhance the outcomes of minimally invasive and other gynecological surgical procedures, addressing significant unmet needs in the field.

Key Strategic Focus

Rejoni's strategic focus centers on the development of hydrogels designed to prevent intrauterine adhesions (IUA) that can form following transcervical gynecological procedures. Their flagship product, the Juveena™ Hydrogel System, is intended to serve as a temporary implant to maintain uterine cavity integrity during the healing process, thereby reducing the risk of adhesion formation. This focus underscores Rejoni's commitment to improving surgical outcomes and patient quality of life in women's health.

Financials and Funding

Since its inception, Rejoni has successfully secured substantial funding to support its research and development initiatives:

Series A Financing (September 2020): Raised $15 million, led by Ascension Ventures, with participation from Delos Capital and Sparta Group. The funds were allocated to expanding the development team, completing pre-clinical studies, and initiating clinical trials.

Series B Financing (December 2022): Secured $25 million, led by Catalyst Health Ventures, with continued support from existing investors. This capital is intended to complete the pivotal study of the Juveena Hydrogel System and explore additional therapeutic indications in women's health.

Pipeline Development

Rejoni's primary product in development is the Juveena™ Hydrogel System:

Juveena™ Hydrogel System: Designed as a temporary intrauterine implant to prevent intrauterine adhesions post-transcervical gynecological procedures.

Clinical Trials: Currently undergoing a pivotal study under an Investigational Device Exemption (IDE) in the United States. The study commenced patient enrollment in August 2022, with completion anticipated by April 2025.

Milestones: First patients treated in the U.S. IDE pivotal study as of December 2022.

Technological Platform and Innovation

Rejoni distinguishes itself through its proprietary hydrogel technology:

Proprietary Hydrogels: Developed to serve as temporary implants that maintain uterine cavity integrity during healing, thereby preventing adhesion formation.

Scientific Methodologies: Utilizes in situ polymerizing hydrogels, which transition from liquid to gel form upon application, ensuring optimal coverage and efficacy.

Leadership Team

Rejoni's leadership comprises experienced professionals with a strong background in medical technology:

Amarpreet Sawhney, Ph.D. – Founder, Chief Executive Officer, President, and Board Member. A serial entrepreneur, Dr. Sawhney has previously founded Confluent Surgical, Ocular Therapeutix, and Augmenix, Inc.

Nick Svencer – General Manager and Board Member. Brings extensive experience in medical device management and operations.

Competitor Profile

Market Insights and Dynamics

The women's health medical device market is experiencing growth, driven by increasing awareness and demand for minimally invasive surgical solutions. Innovations aimed at improving surgical outcomes and patient quality of life are key drivers in this sector.

Competitor Analysis

Rejoni operates in a competitive landscape with several notable companies:

LiNA Medical: Based in Glostrup, Denmark, LiNA Medical specializes in gynecological surgical instruments and devices.

CooperSurgical: Headquartered in Trumbull, Connecticut, CooperSurgical offers a broad range of products for women's health care, including surgical devices and fertility solutions.

Thomas Medical: Located in Addison, Illinois, Thomas Medical focuses on developing and manufacturing medical devices for gynecological procedures.

These competitors provide a range of gynecological surgical instruments and devices, contributing to the dynamic and evolving market landscape.

Strategic Collaborations and Partnerships

Rejoni has established strategic partnerships with several investors to bolster its market position and innovation capacity:

Catalyst Health Ventures: Led the Series B financing round, providing capital to advance clinical studies and product development.

Ascension Ventures: Led the Series A financing round, supporting early-stage development and clinical trials.

Delos Capital and Sparta Group: Participated in both Series A and B financing rounds, demonstrating continued confidence in Rejoni's mission and products.

Operational Insights

Rejoni's strategic considerations include:

Market Position: Focusing on unmet needs in gynecological surgery, particularly in preventing intrauterine adhesions, to carve a niche in the women's health sector.

Competitive Advantages: Leveraging proprietary hydrogel technology and the expertise of a seasoned leadership team to differentiate from competitors.